Page 206 - Read Online

Page 12 of 13 Suominen et al. J Cancer Metastasis Treat 2019;5:14 I http://dx.doi.org/10.20517/2394-4722.2018.64

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Wilson C, Coleman R. Adjuvant bone-targeted therapies for postmenopausal breast cancer. JAMA Oncol 2016;2:423-4.
2. Body JJ, Terpos E, Tombal B, Hadji P, Arif A, et al. Bone health in the elderly cancer patient: a SIOG position paper. Cancer Treat Rev
2016;51:46-53.
3. Wong M, Pavlakis N. Optimal management of bone metastases in breast cancer patients. Breast Cancer (Dove Med Press) 2011;3:35-60.
4. Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy
analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 2014;15:997-1006.
5. Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental
breast cancer bone metastasis. J Natl Cancer Inst 2007;99:322-30.
6. Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer
cells in bone metastases. Cancer Res 2001;61:4418-24.
7. Zekri J, Mansour M, Karim SM. The anti-tumour effects of zoledronic acid. J Bone Oncol 2014;3:25-35.
8. Suominen MI, Rissanen JP, Käkönen R, Fagerlund KM, Alhoniemi E, et al. Survival benefit with radium-223 dichloride in a mouse model
of breast cancer bone metastasis. J Natl Cancer Inst 2013;105:908-16.
9. Junankar S, Shay G, Jurczyluk J, Ali N, Down J, et al. Real-time intravital imaging establishes tumor-associated macrophages as the
extraskeletal target of bisphosphonate action in cancer. Cancer Discov 2015;5:35-42.
10. Rogers TL, Wind N, Hughes R, Nutter F, Brown HK, et al. Macrophages as potential targets for zoledronic acid outside the skeleton-
evidence from in vitro and in vivo models. Cell Oncol (Dordr) 2013;36:505-14.
11. Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous
versus extraosseous breast tumor growth in vivo. Clin Cancer Res 2008;14:4658-66.
12. Brown HK, Ottewell PD, Evans CA, Coleman RE, Holen I. A single administration of combination therapy inhibits breast tumour
progression in bone and modifies both osteoblasts and osteoclasts. J Bone Oncol 2012;1:47-56.
13. Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a
mouse model of breast cancer. J Natl Cancer Inst 2008;100:1167-78.
14. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, et al. Anticancer mechanisms of doxorubicin and zoledronic acid in breast
cancer tumor growth in bone. Mol Cancer Ther 2009;8:2821-32.
15. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, et al. Sustained inhibition of tumor growth and prolonged survival following
sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2010;126:522-32.
16. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, et al. Evidence for a causal role of parathyroid hormone-related protein in the
pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-9.
17. Arguello F, Frantz CN, Baggs RB. Experimental bone and bone marrow metastasis in laboratory animals. J Natl Cancer Inst 1990;82:1069-
70.
18. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in
bone in nude mice. Cancer Res 1995;55:3551-7.
19. Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, et al. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice
with defective osteoclasts. Bone 2009;44:908-16.
20. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on
tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010;102:1099-105.
21. Horiguchi J, Hasegawa Y, Miura D, Ishikawa T, Hayashi M, et al. A randomized controlled trial comparing zoledronic acid plus
chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer. J Clin Oncol
2013;31:1029.
22. Fasching PA, Jud SM, Hauschild M, Kümmel S, Schütte M, et al. FemZone trial: a randomized phase II trial comparing neoadjuvant
letrozole and zoledronic acid with letrozole in primary breast cancer patients. BMC Cancer 2014;14:66.
23. Charehbili A, van de Ven S, Smit VT, Meershoek-Klein Kranenbarg E, Hamdy NA, et al. Addition of zoledronic acid to neoadjuvant
chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG
2010-01). Ann Oncol 2014;25:998-1004.
24. Green JR. Antitumor effects of bisphosphonates. Cancer 2003;97:840-7.
25. Käkönen RS, Rissanen JP, Suominen MI, Halleen JM. Quantitative image analysis method for measuring whole-body tumor burden in a
mouse model of breast cancer bone metastasis. J Bone Miner Res 2008;23:S136-243.
26. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell
2003;3:537-49.
27. Pollari S, Käkönen SM, Edgren H, Wolf M, Kohonen P, et al. Enhanced serine production by bone metastatic breast cancer cells stimulates
osteoclastogenesis. Breast Cancer Res Treat 2011;125:421-30.
28. Pollari S, Leivonen SK, Perälä M, Fey V, Käkönen SM, et al. Identification of microRNAs inhibiting TGF-β-induced IL-11 production in
bone metastatic breast cancer cells. PLoS One 2012;7:e37361.